Close
Close
Treatment News

Reata Announces Late-Breaking Presentation of Primary Results From Phase 2 CARDINAL Study at the American Society of Nephrology Kidney Week 2017 Annual Meeting

3.16666666667
3.2 from 6 votes
Friday, October 20, 2017

Learn more about:

Clinical Trials

IRVING, Texas - Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata" or the "Company") announced that the primary efficacy and safety data from the Phase 2 portion of the CARDINAL study of bardoxolone methyl in Alport syndrome will be presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting being held in New Orleans from Oct. 25-Nov. 5 at the Ernest N. Morial Convention Center.

Geoffrey A. Block, M.D., CCRI, director of clinical research at Denver Nephrology, will present "Initial Data Report from "CARDINAL": A Phase 2/3 Study of Bardoxolone Methyl in Patients with Alport Syndrome," on Friday, Nov. 3 at 10 a.m. CDT.

About Alport Syndrome

Alport syndrome is a rare, genetic form of CKD caused by mutations in the genes encoding type IV collagen, which is a major structural component of the glomerular basement membrane ("GBM") in the kidney. The abnormal expression of type IV collagen causes loss of GBM integrity, abnormal leakage of proteins through the GBM, and excessive reabsorption of protein in the proximal tubules of the kidney. Like other forms of CKD, excessive reabsorption of protein in the tubules induces oxidative stress, chronic inflammation, and renal interstitial inflammation and fibrosis.

Alport syndrome affects approximately 12,000 people in the United States and approximately 40,000 people globally. Almost all patients with Alport syndrome develop end-stage renal disease, and approximately 50% of male patients require dialysis or a kidney transplant by the age of 25. There are currently no approved therapies to treat Alport syndrome.

About Bardoxolone Methyl

Bardoxolone methyl is an experimental, oral, once-daily activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The FDA has granted orphan designation to bardoxolone for the treatment of Alport syndrome. Bardoxolone is also currently being studied in CATALYST, a Phase 3 study for the treatment of connective tissue disease associated pulmonary arterial hypertension.

About Reata Pharmaceuticals, Inc.

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata's two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling.

Source: Reata Pharmaceuticals, Inc.
3.16666666667
3.2 from 6 votes
Free Newsletter
Trending News
Videos
by Abidemi Uruejoma
7 views
by Scott Harwood
7 views
by Scott Harwood
6 views
by Abidemi Uruejoma
32 views
by Scott Harwood
24 views